Registry Trial of the Effectiveness of Platelet Rich Plasma for Chronic Non-Healing Wounds

Inclusion Criteria: * Medicare Eligible * Written informed consent obtained from either the subject or the subject's legally acceptable representative prior to screening activities * Male or female ≥ 18 years of age * Duration of Diabetic Foot Ulcers (DFU),Venous Ulcers (VU), or Pressure Ulcers (PU) is greater than 30 days at first visit/subject screening * DFU is classified as Wagner 1 -2 on the Wagner classification system * If more than one non-healing wound is present, the largest of the wounds that is classified as a Wagner 1 - 2. * If a subject has multiple eligible wounds, the largest wound will be selected. There must be at least 4 cm between the index wound and other wounds; if all wounds are closer than 4 cm, the subject should not be enrolled (screen failure). * The ulcer must be clinically non-infected * Able and willing to comply with the procedures required by the protocol. Subjects may be managed as either inpatient or outpatient. * If a female of childbearing potential, the subject must have a negative urine pregnancy test at screening and must agree to use adequate contraception methods for the duration of the study. * Ankle Brachial Index (ABI) greater than or equal to 0.7. Exclusion Criteria: * Subjects with known sensitivity to components of the Arteriocyte BioBandage™ (calcium chloride, thrombin, acid citrate dextrose solution A (ACDA)). * Current treatment of another chronic wound in the same limb (defined as arm or leg). * Wound is not of DFU, PU, or VU pathophysiology. * PU is classified as late stage III or stage IV. * Confirmed presence of osteomyelitis, or if osteomyelitis is suspected. * Received systemic corticosteroids or immunosuppressive agents, hyperbaric oxygen therapy (HBOT), electrostimulation, growth factors, or any cell or tissue-derived products for wounds during the 30 days preceding the screening visit. * Any chronic condition requiring the use of systemic corticosteroids 30 days prior to study entry and anytime during the course of the study. * Received radiation therapy or chemotherapy within previous 6 months. * Any malignancy other than non-melanoma skin cancer. * Patient has radiographic evidence consistent with diagnosis of neuropathic osteoarthropathy (Charcot foot) in the treatment limb. * Ulcer area decreases by greater than or equal to 30% during screening period * Subjects who are cognitively impaired and do not have a healthcare proxy. * Subject has inadequate venous access for repeated blood draw required for PRP preparation. * Subject has sickle cell anemia. * Subject is pregnant or plans to become pregnant during the duration of the trial. * Concurrent participation in a clinical trial in which an investigational agent is used. * Females who are nursing. * Subjects with Thrombocytopenia \< 100,000 platelets/µL.